RM-GHA / Growth-hormone-axis signalling
Hexarelin
Also known as: Examorelin · EP-23905
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Hexarelin is a synthetic growth-hormone secretagogue peptide. It is not interchangeable with GHRP-2, GHRP-6 or ipamorelin despite shared pathway language.
Evidence position
Controlled human pharmacology studies support Grade B. The record is centered on short-term endocrine responses rather than a validated therapeutic outcome.
What the record does not establish
Published human studies do not verify a separately sourced vial, manufacturing process or lot.
Sources
- 01Growth hormone-releasing activity of hexarelin after multiple administration routesPubMed
- Shows
- Human dose and route comparison in 12 healthy volunteers
- Does not show
- Short endocrine-response study, not clinical effectiveness or supplier validation
- 02Hexarelin dose-response study in healthy human subjectsPubMed
- Shows
- Double-blind placebo-controlled rising-dose pharmacology study
- Does not show
- Twelve adult men and acute exposure only
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Examorelin
- CID
- 6918297
- Formula
- C47H58N12O6
- Mass
- 887.0
PUBMED / FOUND RECORDS
- We are ageing.BioMed research international / 2014PMID 25045704 / DOI 10.1155/2014/808307
- The cardiovascular action of hexarelin.Journal of geriatric cardiology : JGC / 2014 SepPMID 25278975 / DOI 10.11909/j.issn.1671-5411.2014.03.007
- The Safety and Efficacy of Growth Hormone Secretagogues.Sexual medicine reviews / 2018 JanPMID 28400207 / DOI 10.1016/j.sxmr.2017.02.004
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.European journal of medical research / 2023 Sep 14PMID 37710348 / DOI 10.1186/s40001-023-01318-w
- The CD36-PPARγ Pathway in Metabolic Disorders.International journal of molecular sciences / 2018 May 21PMID 29883404 / DOI 10.3390/ijms19051529